Successful Treatment With Infliximab of a Patient With Tumor Necrosis Factor-Associated Periodic Syndrome (TRAPS) Who Failed to Respond to Etanercept

Journal of Rheumatology - Canada
doi 10.3899/jrheum.091094
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The Journal of Rheumatology

Related search

Tumor Necrosis Factor Receptor 1 Associated Periodic Syndrome

2020English

Successful Treatment of Refractory Behçet’s Myositis With Tumor Necrosis Factor Inhibitor

Hong Kong Bulletin on Rheumatic Diseases
2018English

Value of Antidrug Antibody Screening in Moderate-To-Severe Rheumatiod Arthritis Patients Who Failed Initial Tumor Necrosis Factor-Alpha Treatment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Transcriptional Signatures Related to Glucose and Lipid Metabolism Predict Treatment Response to the Tumor Necrosis Factor Antagonist Infliximab in Patients With Treatment-Resistant Depression

Brain, Behavior, and Immunity
EndocrineImmunologyBehavioral NeuroscienceAutonomic Systems
2013English

Infliximab (Anti–Tumor Necrosis Factor Α Antibody)

Archives of Dermatology
2001English

Expression Profiling Identifies Genes That Continue to Respond to Insulin in Adipocytes Made Insulin-Resistant by Treatment With Tumor Necrosis Factor-Α

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2003English

Who Can Respond to Treatment?

Medical Care
EnvironmentalPublic HealthOccupational Health
2010English

Ramsay Hunt Syndrome in a Patient With Rheumatoid Arthritis After Treatment With Infliximab

Case Reports in Rheumatology
2014English

Giant Cell Myocarditis in a Patient With Crohn's Disease, Treated With Etanercept – A Tumour Necrosis Factor-Alpha Antagonist

Canadian Journal of Gastroenterology
2001English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy